International Clinical Trial: A Randomized, Double-blind, Placebo-Controlled Phase I Clinical Trial of the Safety and Tolerability of a Single Administration and dose escalation of Angiotensin II Receptor Type 1 Therapeutic Antihypertensive Vaccine in Healthy Subjects (TAVAR-1)

Geneva, July 7 -- International Clinical Trials Registry received information related to the study (ChiCTR2600127222) titled 'A Randomized, Double-blind, Placebo-Controlled Phase I Clinical Trial of the Safety and Tolerability of a Single Administration and dose escalation of Angiotensin II Receptor Type 1 Therapeutic Antihypertensive Vaccine in Healthy Subjects (TAVAR-1)' on June 26.

Study Type: Interventional study

Study Design: Parallel

Primary Sponsor: Union hospital of Tongji Medical College, Huazhong University of Science and Technology

Condition: Hypertension

Intervention: Experimental group:HJY-ATRQß-001 injection

Recruitment Status: Recruiting

Phase: N/A

Date of First Enrollment: 2026-04-15

Target Sample Size:...